(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Clearside Biomedical (CLSD) said Tuesday that dosing has been completed in cohorts 3 and 4 of its phase 1/2a clinical trial of CLS-AX in patients with...
Excellon Resources (EXN) shares soared 89% after the company disclosed in a filing with the US Securities and Exchange Commission "high-grade" gold...
Expected Earnings Release: 03/10/2022, After-hours Avg. Extended-Hours Dollar Volume: $278,677 Clearside Biomedical Inc (CLSD) is due to issue its...
| Address | 900 North Point Parkway Alpharetta, Georgia 30005 |
| Phone | +1.678.270.3631 |
| Number of Employees | 50 |
| Recent SEC Filing | 08/12/2022 10-Q |
| President, Chief Executive Officer & Director | George M. Lasezkay |
| Chief Financial Officer | Charles A. Deignan |
| Vice President-Engineering & Manufacturing | Rafael V. Andino |
| Vice President-Preclinical Development | Viral Kansara |
| Price Open | $1.57 |
| Previous Close | $1.55 |
| 52 Week Range | $1.26 - 7.73 |
| Market Capitalization | $95.6 M |
| Shares Outstanding | 60.2 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/09/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.03 |
| Beta vs. S&P 500 | N/A |
| Revenue | $30.0 K |
| Net Profit Margin | -5.47% |
| Return on Equity | -6.12% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
